Fig. 1From: Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosisPercent changes in brain volume in multiple sclerosis patients under treatment for two or three years with disease modifying drugs in Phase III Randomized Clinical Trials or observational studies. The estimated ranges of brain volume loss for healthy individuals and relapsing remitting multiple sclerosis are indicated with different shades of greyBack to article page